Silence

According to its CEO, Silence is aiming to expand into a "full-functioning biotech" with more than just a single product.

NEW YORK (GenomeWeb) – Silence Therapeutics this month disclosed that it was ending its work with investigational sepsis drug Atu112 amid disappointing results in preclinical testing.

NEW YORK (GenomeWeb) – Silence Therapeutics this week announced the publication of preclinical data showing that its acute lung injury drug Atu111 could reduce the severity of sepsis-related illness and improve survival in mice.

Key RNAi Drugs in the Clinic

Premium

NEW YORK (GenomeWeb) – With more interest from industry and investors than ever before, the RNAi therapeutics field has a record number of drug candidates in human testing for indications ranging from viral disease to cancer to skin disorders.

NEW YORK (GenomeWeb) – Silence Therapeutics this week announced that it has completed patient recruitment for a Phase IIa trial of its siRNA-based cancer drug Atu027.

Silence Therapeutics this week announced that a collaborator is planning a phase Ib trial of the company's siRNA-based cancer drug Atu027 in combination with the chemotherapeutic agents cisplatin, 5-FU, and cetuximab for head and neck cancer.

Silence Therapeutics said that its executive chairman Jerry Randall has stepped down from his position at the company.

Silence Therapeutics this week announced that its siRNA-based cancer drug Atu027 has progressed into the phase IIa portion of an ongoing phase Ib/IIa trial.

Silence Therapeutics this week announced that it has begun dosing patients in a phase Ib/IIa clinical trial of its cancer treatment Atu027 in combination with chemotherapy after having identified the drug’s maximum tolerated dose in a phase I study last year.

Silence Therapeutics this week announced that it is closing in on a much-needed financial shot in the arm, inking deals to raise £18.7 million ($28.6 million) through the private placement of 9.5 million shares to certain investors.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.